Showing 3971-3980 of 8897 results for "".
- ICONIC-TOTAL: Icotrokinra Shows Skin Clearance in Difficult-to-Treat PsO at 1 Yearhttps://practicaldermatology.com/news/iconic-total-icotrokinra-shows-skin-clearance-in-difficult-to-treat-pso-at-1-year/2484061/Icotrokinra, a novel oral IL-23 inhibitor, was associated with imporvements in plaque psoriasis in difficult-to-treat areas of the body, according to new data presented at 2025 Fall Clinical Dermatology Conference in Las Vegas.
- Dr. Woolery-Lloyd Appointed Program Development Advisor for Skin of Color Updatehttps://practicaldermatology.com/news/dr-woolery-lloyd-appointed-program-development-advisor-for-skin-of-color-update/2484015/Heather Woolery-Lloyd, MD, FAAD, has been appointed program development advisor for Skin of Color Update, the nation’s largest medical education event focused on dermatologic care for patients with skin of color. Dr. Woolery-Lloyd serves as director of the Skin of Color Division at the Uni
- Study: Low-Calorie Diet May Increase PsA Riskhttps://practicaldermatology.com/news/study-low-calorie-diet-may-increase-psa-risk/2483973/A low-calorie diet may increase the risk of developing psoriatic arthritis, according to findings from a Mendelian randomization (MR) study published in Clinical, Cosmetic and Investigational Dermatology.
- Analysis: Long-Term Ixekizumab Not Linked to Higher Cancer Risk in PsO, PsAhttps://practicaldermatology.com/news/analysis-long-term-ixekizumab-not-linked-to-higher-cancer-risk-in-pso-psa/2483983/A recent pooled analysis of 25 randomized clinical trials (RCTs) found no increased risk of malignant neoplasms with long-term ixekizumab (IXE) therapy in patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).
- Risk-Guided Screening Enhances Early Skin Cancer ID in Transplant Cohorthttps://practicaldermatology.com/news/risk-guided-screening-enhances-early-skin-cancer-id-in-transplant-cohort/2483972/A risk-based skin cancer surveillance strategy was associated with improved early detection rates among solid organ transplant (SOT) recipients, according to findings from a recent retrospective cohort analysis of the implementation of the KP-SUNTRAC program across K
- Study Links Structural and Immune Risk Factors to Skin Conditions in PWHhttps://practicaldermatology.com/news/study-links-structural-and-immune-risk-factors-to-skin-conditions-in-pwh/2483949/Nearly half of people living with HIV (PWH) are diagnosed with at least one dermatologic condition despite advances in antiretroviral therapy (ART), according to a longitudinal cohort study published through the DC Cohort. Accor
- Global CME Conference to Spotlight Eczema Burden, Treatment Advanceshttps://practicaldermatology.com/news/global-cme-conference-to-spotlight-eczema-burden-treatment-advances/2483912/Health & Wellness Global Alliance will host its inaugural H&W Global Dermatology CME Conference November 12-16, 2025, aiming to spotlight the international burden of eczematous diseases. The event aligns with the mission
- FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCChttps://practicaldermatology.com/news/fda-approves-libtayo-for-adjuvant-treatment-of-high-risk-cscc/2483899/The FDA has approved cemiplimab-rwlc (Libtayo, Regeneron) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence following surgery and radiation, according to a statement from the agency.
- Pfizer and GWU Renew Grant Program to Expand Teledermatology Access for Inflammatory Skin Conditionshttps://practicaldermatology.com/news/pfizer-and-gwu-renew-grant-program-to-expand-teledermatology-access-for-inflammatory-skin-conditions/2483889/Pfizer Global Medical Grants and The George Washington University (GWU) have renewed their joint grant program focused on broadening access to dermatologic care in underserved U.S. communities. According to a GWU press announc
- Analysis: Ceramide Skincare from Birth May Mitigate Pediatric ADhttps://practicaldermatology.com/news/analysis-ceramide-skincare-from-birth-may-mitigate-pediatric-ad/2483872/A new consensus paper offers clinical recommendations to address the complex interplay of skin barrier dysfunction and SAIGE (Staphylococcus aureus colonization, immunologic, genetic, and environmental) factors in pediatric atopic dermatitis (AD).